<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80748">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02091947</url>
  </required_header>
  <id_info>
    <org_study_id>201010015OB</org_study_id>
    <nct_id>NCT02091947</nct_id>
  </id_info>
  <brief_title>Efficacy of Functional Magnetic Stimulation in Urinary Incontinence</brief_title>
  <acronym>FMS</acronym>
  <official_title>Efficacy of Functional Magnetic Stimulation in Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vghtpe user</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <authority>Taiwan : Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional Magnetic Stimulation (FMS) appears to modulate autonomic and somatic nervous
      systems that innervate the lower urinary tract. Stimulation of the pudendal afferent nerve
      near the third sacral root induces relaxation of the detrusor muscles and reinforcement of
      urethral sphincter. Some preliminary studies had indicated the positive effect of FMS on
      stress urinary incontinence. Investigators aimed to evaluate the immediate and long-term
      effect of this method on stress urinary incontinent patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5 Hz repetitive magnetic stimulation was applied over bilateral sacral roots for 20 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Symptom scoring on Urge-Urinary Distress Inventory questionnaire</measure>
    <time_frame>up to 5 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cystometry and stress urethral pressure profile as measures of objective incontinence improvement</measure>
    <time_frame>up to 5 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Incontinence</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Real FMS, 5 Hz, 20 minutes per day, for 10 weekdays.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham FMS, 5 Hz, 20 min per day, for 10 weekdays.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FMS (Magstim rapid2)</intervention_name>
    <description>5 Hz FMS, over bilateral sacral roots.</description>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_label>sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Urine incontinence refractory to traditional treatment

        Exclusion Criteria:

          -  Arrhythmia, pacemaker implantation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Po-Yi Tsai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep of PMR, Taipei VGH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Po-Yi Tsai, MD</last_name>
    <phone>886-28757293</phone>
    <email>pytsai@vghtpe.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Veteran General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po-Yi Tsai, MD</last_name>
    </contact>
    <investigator>
      <last_name>Po-Yi Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>March 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Veterans General Hospital, Taiwan</investigator_affiliation>
    <investigator_full_name>vghtpe user</investigator_full_name>
    <investigator_title>Po-Yi Tsai MD</investigator_title>
  </responsible_party>
  <keyword>FMS</keyword>
  <keyword>Urine incontinence</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
